Evidence map›Paper›PMID 38254245›Full record

ArticleActa neuropathologica communications2024

Missense mutation of NRAS is associated with malignant progression in neurocutaneous melanosis.

Haruhiko Takahashi, Manabu Natsumeda, Norikazu Hara, Akihide Koyama, Hiroshi Shimizu, Akinori Miyashita, Daiken Satake, Yoshihiro Mouri, Jun Tsukano, Keita Kawabe and 8 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Acta neuropathologica communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Impact of chemotherapy and immunotherapy on survival in pediatric primary diffuse leptomeningeal melanomatosis: a systematic review and pooled survival analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Haruhiko TakahashiDepartment of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Manabu NatsumedaDepartment of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan. natsumeda@bri.niigata-u.ac.jp.ORCID 0000-0003-3098-8323
Norikazu HaraDepartment of Molecular Genetics, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Akihide KoyamaDepartment of Legal Medicine, Graduate School of Medical and Dental Science, Niigata University, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8510, Niigata, Japan.
Hiroshi ShimizuDepartment of Pathology, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Akinori MiyashitaDepartment of Molecular Genetics, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Daiken SatakeDepartment of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Yoshihiro MouriDepartment of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Jun TsukanoDepartment of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Keita KawabeDepartment of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Yoshihiro TsukamotoDepartment of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Masayasu OkadaDepartment of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Ryosuke OguraDepartment of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Akihiko YukiDivision of Dermatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8510, Niigata, Japan.
Hajime UmezuDivision of Pathology, Niigata University Medical and Dental Hospital, Niigata University, 1-754 Asahimachi, Chuo-ku, 951-8510, Niigata, Niigata, Japan.
Akiyoshi KakitaDepartment of Pathology, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Takeshi IkeuchiDepartment of Molecular Genetics, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Makoto OishiDepartment of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, 951-8585, Niigata, Japan.
Niigata University · JPNiigata University Medical and Dental Hospital · JP

Funding

AMED JP23dk0207060Japanese Society for Promotion of Science KAKENHI 22K16679Japan Research Promotion Society for KAKENHI 21KK0156
6 · The paper itself

Abstract

Neurocutaneous melanosis (NCM) is a rare congenital neurocutaneous syndrome characterized by congenital melanocytic nevus of skin and abnormal proliferation of leptomeningeal melanocytes. Early acquisition of post-zygotic somatic mutations has been postulated to underlie the pathogenesis of NCM. The pathogenesis of NCM remains to be fully elucidated, and treatment options have not been established. Here, we report for the first time, multiregional genomic analyses in a 3-year-old autopsied girl with leptomeningeal melanomatosis associated with NCM, in which a ventriculo-peritoneal (VP) shunt was inserted for the treatment of hydrocephalus. The patient expired six months after the onset due to respiratory failure caused by abdominal dissemination via VP shunt. We performed multiregional exome sequencing to identify genomic differences among brain and abdominal tumors, nevus, and normal tissues. A total of 87 somatic mutations were found in 71 genes, with a significantly large number of gene mutations found in the tumor site. The genetic alterations detected in the nevus were only few and not shared with other sites. Three mutations, namely GNAQ R183Q, S1PR3 G89S and NRAS G12V, considered pathogenic, were found, although S1PR3 mutations have not been previously reported in melanocytic tumors. GNAQ and S1PR3 mutations were shared in both tumor and normal sites. Moreover, the mutant allele frequencies of the two mutations were markedly higher in tumor sites than in normal sites, with copy-neutral loss-of-heterozygosity (CN-LOH) occurring in tumor. NRAS mutation was found only in the abdominal tumor and was thought to be responsible for malignant progression in the present case. Multiregional comprehensive genetic analysis may lead to discovering novel driver mutations associated with tumorigenesis and targeted therapy.

Indexed as

MelanosisNeurocutaneous SyndromesNevusSkin NeoplasmsChild, PreschoolFemaleGTP PhosphohydrolasesHumansMembrane ProteinsMutation, MissenseGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanDroplet digital polymerase chain reactionMultiregional genomic analysisNeurocutaneous melanosisWhole exome sequencing

Identifiers

PMID38254245
PMCPMC10804483
OpenAlexW4391100045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.